Thursday, April 24, 2014

Cynapsus files final short-form prospectus for offering

Cynapsus files final short-form prospectus for offering

April 9, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a final short-form prospectus in British Columbia, Alberta and Ontario to sell a minimum of 23,076,923 units and a maximum of 38,461,538 units at a price of 65 cents each for gross proceeds of $15-million to $25-million. Each unit consists of one common share and one warrant. Each […]

Cynapsus files for financing

Cynapsus files for financing

March 31, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a preliminary short-form prospectus with securities agencies in the provinces of British Columbia, Alberta and Ontario for a best-efforts offering of common shares and warrants for gross proceeds of $15-million to $25-million. The final pricing and the number of common shares and warrants to be sold will occur […]

Cynapsus finds 25-mg APL-130277 strip safe

Cynapsus finds 25-mg APL-130277 strip safe

March 28, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive interim data from its recently completed healthy volunteer pilot study of a single 25-milligram sublingual strip (APL-130277) dose of apomorphine. The interim CTH-104 study results indicate that a higher load of drug on the strip results in a higher amount of drug entering the blood stream. “Results […]

Cynapsus gains DTC approval

Cynapsus gains DTC approval

February 27, 2014 by · Leave a Comment 

Tweet Common shares of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) have been made eligible for book-entry delivery and depository services of The Depository Trust Co. (DTC) to facilitate electronic settlement of transfers of its common shares in the U.S. “The ability to have Cynapsus shares electronically transferred between brokerages in the United States is significantly more convenient […]

Cynapsus PD data: couldn’t have wished for anything better

Cynapsus PD data: couldn’t have wished for anything better

February 18, 2014 by · Leave a Comment 

Tweet “If I had asked for a gift, I couldn’t have wished for anything better,” says Anthony Giovinazzo, president and CEO of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH). He was referring to a recently completed healthy volunteer pilot crossover trial, CTH103, which compared Cynapsus’ APL-130277, a sublingual thin film strip formulation of apomorphine, with a commercially available […]

Cynapsus names Nan Hutchinson to board

Cynapsus names Nan Hutchinson to board

February 13, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Nan Hutchinson to its board. Over the past decade, Ms. Hutchinson was the SVP of marketing and sales for URL Pharma, helping transform the commercial organization and leading to the acquisition by Takeda Pharmaceutical. Prior to URL, she was SVP of marketing at Bristol-Myers Squibb where she ran […]

Cynapsus to start trading on OTCQX International

Cynapsus to start trading on OTCQX International

July 18, 2013 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) common shares have been approved for trading in the U.S. on the OTCQX marketplace, with trading  to commence immediately under the symbol CYNAF. Trading will continue to trade on the TSX Venture Exchange under its existing symbol CTH. OTCQX International is a segment of the OTCQX marketplace reserved for high-quality, […]

Noble starts Cynapsus at buy

Noble starts Cynapsus at buy

July 9, 2013 by · Leave a Comment 

Tweet Noble Financial Capital Markets has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and 12-month price target of $1.75. The stock closed at 38 cents on Monday. Cynapsus is currently advancing APL-130277, a first-in-class film strip of an already approved drug, Apokyn, for the treatment of Parkinson’s disease, with an expected patent […]

Zacks starts Cynapsus at buy

Zacks starts Cynapsus at buy

June 4, 2013 by · Leave a Comment 

Tweet Zachs Research has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and price target of $1.25, calling the company an “undiscovered gem.” The stock was quoted at 40 cents Tuesday afternoon. “Despite limited volume and a market capitalization well below that of our typical coverage universe, we believe the company’s focus on […]

Cynapsus names Dexcel execs to its board

Cynapsus names Dexcel execs to its board

May 10, 2013 by · Leave a Comment 

Tweet Tomer Gold, VP of R&D, of closely-held Dexcel Pharma, and Ilan Oren, VP of business development at Dexcel, have joined the board of Cynapsus Therapeutics (TSX-V:CTH). Dexcel recently acquired 7,608,696 units of Cynapsus for $3.5-million, resulting in a 19.6% and 24% holding of Cynapsus outstanding stock on a basic and fully diluted basis, respectively. […]

Next Page »

Google+